ReviewBiomolecules2020
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 215 citations in OpenAlex.
- Pooled it
- Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.PloS one · 2021Pooled it
- Effect of ivarmacitinib on swelling and tenderness in small and large joints and imaging changes in patients with moderate-to-severe RA: a post hoc analysis of a phase III clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.Arthritis research & therapy · 2022Trial
- Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs.Rheumatology and therapy · 2026Article
- Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.Clinical rheumatology · 2026Article
- Review
- Menstrual characteristics among rheumatoid arthritis patients receiving Janus kinase inhibitor, biologics, or methotrexate.Internal and emergency medicine · 2026Article
- Osteoarthritis and rheumatoid arthritis: A comparative review of pathophysiology, diagnosis and evolving management.Journal of Taibah University Medical Sciences · 2026Review
- Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function.Cell death & disease · 2026Article
- Research progress in electrochemical determination of Janus kinase inhibitors and proposals for amplifying clinical applicability.Mikrochimica acta · 2026Review
- Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy.BMC rheumatology · 2026Article
- Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.Rheumatology and therapy · 2026Article
- JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review.Pediatric rheumatology online journal · 2026Review
- Recent Advancement in Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.Current drug discovery technologies · 2026Review
- Connection Between Mitochondria and Rheumatoid Arthritis and Osteoarthritis: Personalized Treatment Strategies.Current pharmaceutical design · 2026Review
- Review
- High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.Frontiers in bioengineering and biotechnology · 2026Article
- Machine learning analysis of treatment and complication patterns in rheumatoid arthritis case reports (1995-2025).Reumatologia · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are characterized by a novel mechanism of action, consisting of the intracellular interruption of the JAK-STAT pathway crucially involved in the immune response. The aim of this narrative review is to globally report the most relevant pharmacological features and clinical outcomes of the developed and incoming JAKi for RA, based on the available preclinical and clinical evidence. A total of 219 papers, including narrative and systematic reviews, randomized controlled trials (RCTs), observational studies, case reports, guidelines, and drug factsheets, were selected. The efficacy and safety profile of both the first generation JAKi (baricitinib and tofacitinib) and the second generation JAKi (upadacitinib, filgotinib, peficitinib, decernotinib and itacitinib) were compared and discussed. Results from RCTs and real-life data are encouraging and outline a rapid onset of the pharmacologic effects, which are maintained during the time. Their efficacy and safety profile are comparable or superior to those of biologic agents and JAKi proved to be efficacious when given as monotherapy. Finally, the manufacturing of JAKi is relatively easier and cheaper than that of biologics, thus increasing the number of compounds being formulated and tested for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.